s6y

Opus Genetics, Inc.

Ticker
IRD
CIK
1228627
Industry
Pharmaceutical Preparations
Formerly
Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK

Financials 83

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 83 financials filings

News 227

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 227 news filings

Ownership 453

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 453 ownership filings

Prospectus 80

  1. S-3 Registration statement for specified transactions by certain issuers
  2. 424B2 Prospectus filed pursuant to Rule 424(b)(2)
  3. S-3 Registration statement for specified transactions by certain issuers
  4. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  5. S-3/A Registration statement for specified transactions by certain issuers
  6. S-3 Registration statement for specified transactions by certain issuers
  7. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  8. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 80 prospectus filings

Proxies 70

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DFAN14A Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. PRRN14A Revised preliminary proxy statement filed by non-management
  9. DEFC14A Definitive proxy statement in connection with contested solicitations
  10. DFAN14A Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material

All 70 proxies filings

Other 162

  1. SCHEDULE 13G/A
  2. SCHEDULE 13G
  3. SCHEDULE 13G/A
  4. SCHEDULE 13G
  5. SCHEDULE 13G/A
  6. SCHEDULE 13G/A
  7. 144 Filing for proposed sale of securities under Rule 144
  8. SCHEDULE 13G
  9. 144 Filing for proposed sale of securities under Rule 144
  10. 144 Filing for proposed sale of securities under Rule 144

All 162 other filings